{
    "clinical_study": {
        "@rank": "120890", 
        "arm_group": {
            "arm_group_label": "Epirubicin", 
            "arm_group_type": "Experimental", 
            "description": "Following genetic analysis, depending on results, participants will receive either standard or increased epirubicin dosing for cycles 2 - 4."
        }, 
        "brief_summary": {
            "textblock": "Epirubicin is a common chemotherapy medication used in the treatment of breast cancer.\n      However, chemotherapy dosing is calculated based on people's height and weight, which may\n      not be the most accurate way. The purpose of this study is to see if epirubicin dosing based\n      on people's genetic profiles is better than the usual methods."
        }, 
        "brief_title": "A Study of Genetic Based Chemotherapy Dosing for Breast Cancer Patients", 
        "completion_date": {
            "#text": "June 2025", 
            "@type": "Anticipated"
        }, 
        "condition": "Breast Neoplasms", 
        "condition_browse": {
            "mesh_term": [
                "Breast Neoplasms", 
                "Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Female patients with histologically confirmed non-metastatic invasive breast cancer\n             who are scheduled to receive at least three cycles of FEC100 in the adjuvant or\n             neoadjuvant setting\n\n          2. Documented pathological evaluation of the breast cancer for hormone receptor\n             (estrogen receptor [ER], progesterone receptor [PR] and HER-2 status\n\n          3. Eastern Cooperative Oncology (ECOG) performance status of \u2264 2\n\n          4. A Left Ventricular Ejection Fraction (LVEF) \u2265 50%.\n\n        Exclusion Criteria:\n\n          1. Uncontrolled congestive heart failure (CHF) or angina, history of myocardial\n             infarction within 2 months before study enrollment, or cardiac functional capacity\n             Class III or IV as defined by the New York Heart Association Classification.\n\n          2. Psychiatric disorder(s) that would interfere with consent, study participation, or\n             follow up."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "48", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 16, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01740271", 
            "org_study_id": "FEC100-01"
        }, 
        "intervention": {
            "arm_group_label": "Epirubicin", 
            "intervention_name": "Epirubicin", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Epirubicin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "breast cancer", 
            "non-metastatic carcinoma of the breast chemotherapy", 
            "adjuvant therapy", 
            "neoadjuvant"
        ], 
        "lastchanged_date": "January 29, 2014", 
        "location": {
            "contact": {
                "last_name": "Michael Sawyer, MD", 
                "phone": "780-432-8248"
            }, 
            "facility": {
                "address": {
                    "city": "Edmonton", 
                    "country": "Canada", 
                    "state": "Alberta", 
                    "zip": "T6G 1Z2"
                }, 
                "name": "Cross Cancer Institute"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "1", 
        "official_title": "Pharmacogenetic Dosing of Epirubicin in FEC Chemotherapy", 
        "overall_contact": {
            "email": "denise.brown3@albertahealthservices.ca", 
            "last_name": "Denise Brown, RN MN", 
            "phone": "780-432-8956"
        }, 
        "overall_official": [
            {
                "affiliation": "AHS Cancer Control Alberta", 
                "last_name": "Michael B Sawyer, MD FRCPC BScPharm", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "AHS Cancer Control Alberta", 
                "last_name": "John R Mackey, MD FRCPC", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Canada: Health Canada", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Primary Objectives To describe the side effects of pharmacogenetically individualized FEC chemotherapy in the adjuvant and neoadjuvant treatment of breast cancer.", 
            "measure": "The goal of this study is to determine the safety of pharmacogenetic guided dosing of epirubicin for each UGT2B7 genotype.", 
            "safety_issue": "Yes", 
            "time_frame": "10 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01740271"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Secondary Objectives i) To verify relationships between uridine glucuronosyltransferase 2B7 polymorphisms and epirubicin pharmacokinetics ii) To verify relationships between body composition and epirubicin pharmacokinetics", 
            "safety_issue": "Yes", 
            "time_frame": "10 years"
        }, 
        "source": "AHS Cancer Control Alberta", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AHS Cancer Control Alberta", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}